Download PDF
Thromb Haemost 1997; 78(01): 141-144
DOI: 10.1055/s-0038-1657517
Venous thromboembolism and cancer, a two-way clinical association
Schattauer GmbH Stuttgart

Antithrombotic Strategies in Patients with Cancer

Paolo Prandoni
Institute of Medical Semeiotics, University of Padova, Padova, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
30 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • references

  • 1 Sproul EE. Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am J Cancer 1938; 34: 566-585
    PubMedGoogle Scholar
  • 2 Ambrus JL, Ambrus CM, Mink IB, Pickren JW. Causes of death in cancer patients. J Med 1975; 06: 61-64
    PubMedGoogle Scholar
  • 3 Kakkar VV, Howe CT, Nicolaides AN, Renney JTG, Clarke MB. Deep vein thrombosis of the leg. Is there a “high risk” group?. Am J Surg 1970; 120: 527-530
    CrossrefPubMedGoogle Scholar
  • 4 Hills NH, Pflug JJ, Jeyasingh K, Boardman L, Calnan JS. Prevention of deep vein thrombosis by intermittent pneumatic compression of calf. Br Med J 1972; 01: 131-135
    CrossrefPubMedGoogle Scholar
  • 5 Walsh JJ, Bonnar J, Wright FW. A study of pulmonary embolism and deep vein thrombosis after major gynaecological surgery using labelled fibrinogen-phlebography and lung scanning J Obstet Gynaecol Br Commonw. 1974; 81: 311-316
    PubMedGoogle Scholar
  • 6 Sue-Ling HM, Johnston D, McMahon MU, Philips PR, Davies JA. Preoperative identification of patients at high risk of deep venous thrombosis after elective major abdominal surgery. Lancet 1986; 01: 1173-1176
    PubMedGoogle Scholar
  • 7 Carson JL, Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevsky HI, Sanford SchwartzJ, Taylor Thompson B, Popovich J, Hobbins TE, Spera MA, Alavi A, Terrin ML. The clinical course of pulmonary embolism. N Engl J Med 1992; 326: 1240-1245
    CrossrefPubMedGoogle Scholar
  • 8 Nand S, Fischer SG, Salgia R, Fisher RI. Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications. J Clin Oncol 1987; 05: 1998-2003
    CrossrefPubMedGoogle Scholar
  • 9 Nanninga PB, van TeunenbroekA, Veenhof CHN, Büller HR, ten CateJW. Low prevalence of coagulation and fibrinolytic activation in patients with primary untreated cancer. Thromb Haemostas 1990; 64: 361-364
    PubMedGoogle Scholar
  • 10 Luzzatto G, Schafer AI. The prethrombotic state in cancer. Semin Oncol 1990; 17: 147-159
    PubMedGoogle Scholar
  • 11 Prandoni P, Lensing AWA, Büller HR, Cogo A, Prins MH, Cattelan AM, Cuppini S, Noventa F, ten CateJW. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327: 1128-1133
    CrossrefPubMedGoogle Scholar
  • 12 Shen VS, Poliak EW. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified?. South Med J 1980; 73: 841-843
    CrossrefPubMedGoogle Scholar
  • 13 Huber O, Bounameaux H, Borst F, Rohner A. Postoperative pulmonary embolism after hospital discharge. An underestimated risk. Arch Surg 1992; 127: 310-313
    CrossrefPubMedGoogle Scholar
  • 14 Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen: a study of 159 patients. Cancer 1984; 54: 1264-1268
    CrossrefPubMedGoogle Scholar
  • 15 Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Htyniuk W, De PauwS. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988; 318: 404-407
    CrossrefPubMedGoogle Scholar
  • 16 Lokich JJ, Becker B. Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy. Cancer 1983; 52: 1586-1589
    CrossrefPubMedGoogle Scholar
  • 17 Bern MM, Bothe Jr A, Bistrian B, Champagne CD, Keane MS, Blackburn GL. Prophylaxis against central vein thrombosis with low-dose warfarin. Surgery 1986; 99: 216-221
    PubMedGoogle Scholar
  • 18 European Consensus Statement. Prevention of venous thromboembolism. Intern Angiol 1992; 11: 151-159
    PubMedGoogle Scholar
  • 19 Gallus A, Cade J, Ockelford P, Hepburn S, Maas M, Magnani H, Bucknall T, Stevens J, Porteous F. Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double-blind, randomised, multicenter comparison. Thromb Haemostas 1993; 70: 562-567
    PubMedGoogle Scholar
  • 20 Godwin J. Use of low molecular weight heparins in malignancy-related thromboembolic disorders: a clinical review. Clin Appl Thrombosis/Hemostasis 1996; 02 (Suppl. 01) 28-34
    PubMedGoogle Scholar
  • 21 Bergqvist D, Burmark US, Flordal PA, Frisell J, Hallbook T, Hedberg M, Horn A, Kelty E, Kvitting P, Lindhagen A, Ljungstrom KG, Matzsch T, Risberg B, Syk I, Torngren S, Wellander E, Ortenwall P. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 Xal units in 2070 patients. Br J Surg 1995; 82: 496-501
    CrossrefPubMedGoogle Scholar
  • 22 Levine MN, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, Samosh M, Bramwell V, Pritchard KI, Steward D, Goodwin P. Double-blind randomized trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886-889
    CrossrefPubMedGoogle Scholar
  • 23 Bern MM, Lokich JJ, Wallach SR, Bothe A Jr, Benotti PN, Arkin CF, Greco FA, Huberman M, Moore C. Very low doses of warfarin can prevent thrombosis in central venous catheters. Ann Intern Med 1990; 112: 423-428
    CrossrefPubMedGoogle Scholar
  • 24 Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, Abad A. Upper extremity deep venous thrombosis in cancer patients with venous access devices. Prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemostas 1996; 75: 251-253
    PubMedGoogle Scholar
  • 25 Hirsh J, Salzman EW, Marder VJ. Treatment of venous thromboembolism. In Colman RW, Hirsh J, Marder VJ, Salzman EW. (edit) Hemostasis and Thrombosis, basic principles and clinical practice. JB Lippineott Company; Philadelphia: 1993: 1346-1366
    Google Scholar
  • 26 Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bemardi E, Prins MH. The longterm clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 01-07
    CrossrefPubMedGoogle Scholar
  • 27 The Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for deep-vein thrombosis and pulmonary embolism. Submitted.
    PubMedGoogle Scholar
  • 28 Zacharski LR, Henderson WG, Forman WB, Edwards RL, Cornell CJ, Forcier RJ, Headley E, Kim S, O’Donnell JF, O’Dell R, Tornyos K, Kwaan HC. Bleeding complications from warfarin anticoagulation in patients with malignancy. J Med 1985; 16: 535-561
    PubMedGoogle Scholar
  • 29 Bona RD, Sivjee KY, Hickey AD, Wallace DM, Wajcs SB. The efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemostas 1995; 74: 1055-1058
    PubMedGoogle Scholar
  • 30 Zacharski LR, Henderson WG, Rickies FR, Forman WB, Cornell Jr CJ, Forcier RJ, Edwards RL, Headley E, Kim SH, O’Donnell JR, O’Dell RO, Tornyos K, Kwaan HC. Effect of warfarin on survival in small cell carcinoma of the lung. JAMA 1981; 245: 831-835
    CrossrefPubMedGoogle Scholar
  • 31 Prandoni P, Lensing AWA, Büller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten Cate JW. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339: 441-445
    CrossrefPubMedGoogle Scholar
  • 32 Hull RD, Raskob GL, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lemer RG, Hall J, Sparling T, Brettell JN, Carter CJ, George R, Merli G, Ward J, Mayo W, Rosenbloom D, Brant R. Subcutaneous low molecular-weight heparin compared with intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-982
    CrossrefPubMedGoogle Scholar
  • 33 Green D, Hull RD, Brant R, Pineo GF. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 1992; 339: 1476
    PubMedGoogle Scholar